Watchlist Price Alert

NeoGenomics Inc. (NEO)

NASDAQ: NEO · Real-Time Price · USD

8.03

-0.10 (-1.23%)

At close: May 09, 2025, 3:59 PM

8.05

0.25%

After-hours: May 09, 2025, 04:05 PM EDT

-1.23% (1D)

Bid	5.82
Market Cap	206.68M
Revenue (ttm)	672.36M
Net Income (ttm)	-77.59M
EPS (ttm)	-0.61
PE Ratio (ttm)	-13.16
Forward PE	22.9
Analyst	Buy

Ask	8.35
Volume	696,221
Avg. Volume (20D)	2,072,649
Open	8.07
Previous Close	8.13
Day's Range	7.98 - 8.28
52-Week Range	6.08 - 19.11
Beta	1.60

About NEO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol NEO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for NEO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

NeoGenomics has released their quartely earnings on Apr 29, 2025:

Revenue of $168.03M misses estimates by $2.87M, with 7.55% YoY growth.

EPS of 0 exceeds estimates by 0.01, with 100.00% YoY growth.

Why Price Moved

1 week ago

-2.74%

NeoGenomics shares are trading lower after Leerink... Unlock content with Pro Subscription

1 week ago

-34%

NeoGenomics shares are trading lower following a Q1 revenue miss.

News

2 days ago · marketbeat.com

It's Not Too Late to Jump on These Under-the-Radar Momentum Plays

Those subscribing to a momentum investing strategy tend to believe that stocks experiencing price increases tend to rally, so long as both internal and external conditions don't change. Of course, no ...

1 week ago · businesswire.com

NeoGenomics Pays Off 1.25% Convertible Senior Notes

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes.

1 week ago · seekingalpha.com

NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade)

NeoGenomics' recent 32.23% stock price decline post-Q1 earnings miss is seen as a buying opportunity due to overreaction and long-term growth potential. Despite a slight revenue miss, the company's lo...

1 week ago · seekingalpha.com

NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript

NeoGenomics, Inc (NASDAQ:NEO ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Tony Zook - Chief Executive O...

1 week ago · zacks.com

NeoGenomics (NEO) Reports Break-Even Earnings for Q1

NeoGenomics (NEO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.02 per share a year ago.

1 week ago · businesswire.com

NeoGenomics Reports First Quarter 2025 Results

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2025.

2 weeks ago · zacks.com

NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · businesswire.com

NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced analytical validation of its PanTracer LBx™ assay, to be presented with five other abstracts at the AACR Annual Meeting 2025.

1 month ago · businesswire.com

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025.

1 month ago · businesswire.com

NeoGenomics Completes Acquisition of Pathline

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey.

Load More News